The phase II COAST clinical trial demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center, Cancer Center of Kansas, University of Colorado, Abramson Cancer Center, Astrazenaca, and collaborating international organizations.
The American Society of Clinical Oncology published an update expanding the utility of Breast Cancer Index, developed by Hologic Inc., within its Clinical Practice Guideline, “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.”
A commentary authored by seven researchers who participated in the FDA Oncology Center of Excellence “Conversations on Cancer,” held July 29, 2021, discussed the significant cancer disparities facing Asian Americans.
Researchers from The Wistar Institute identified proteins in Epstein-Barr virus-infected cells that decreased expression of genes linked to the spread of the virus, with implications for cancer research.
NEXT Oncology – Madrid enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer with an anti-drug conjugate used in monotherapy or in combination with antiPDL1. NEXT Oncology expanded to Spain in late 2021.
A study led by MedUni Vienna showed that, due to the omicron variant of COVID-19, there is an increasing number of breakthrough infections in people with cancer, especially those undergoing cancer therapy.
Acute lymphoblastic leukemia cells from patients whose cancers did not respond to CD19-targeted CAR T-cell therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the 2022 AACR annual meeting, April 8-13.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer, researchers from The University of Texas MD Anderson Cancer Center reported at the 2022 AACR annual meeting.
Researchers at The University of Texas MD Anderson Cancer Center have developed a bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations. In retrospective validation studies, the tool selected combinations that resulted in improved patient outcomes across both pre-clinical and clinical studies.
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.
